Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:GH 30 October 2025 - 21 January 2026

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck shares rose 0.6% to $109.45 Tuesday, defying a broad U.S. market selloff. Five-year data showed its personalized melanoma vaccine with Moderna cut recurrence or death risk by 49% in a Phase 2b trial. Investors await Phase 3 trial timing and Merck’s Feb. 3 earnings call for more details. The S&P 500 fell 2.06% and Nasdaq lost 2.39%.
21 January 2026
·····
Guardant Health stock jumps 7% as Evercore downgrades — what investors watch next

Guardant Health stock jumps 7% as Evercore downgrades — what investors watch next

Guardant Health shares jumped 7.2% to $109.24 Tuesday, nearing their 52-week high, despite Evercore ISI downgrading the stock while raising its price target to $105. A Form 4 filing showed Chief People Officer Terilyn J. Monroe received 17,555 shares through vested stock units. Shares have climbed about 200% in the past year. Investors are watching Medicare reimbursement rates for Guardant’s Shield blood test.
6 January 2026
·
Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health shares soared nearly 30% to around $94 on Oct. 30, 2025, after Q3 revenue jumped 39% to $265.2 million, beating estimates. The company raised its 2025 revenue outlook to $965–970 million. New partnerships are expanding access to its Shield colorectal cancer test nationwide. Guardant360 received additional FDA approvals and a formal review submission.
30 October 2025
··

Stock Market Today

  • TCS.NS Drops 3.47% to INR 2356 on AI Revenue Outlook and Market Pressure
    March 20, 2026, 9:18 AM EDT. Tata Consultancy Services (TCS.NS) fell 3.47% to INR 2356 on March 20, 2026, amid short-term technical weakness and mixed valuation signals. The stock trades with a trailing PE of 17.88 and EPS of 131.78, reflecting modest valuation in a slowing revenue growth environment. Strong cash flow and dividend yield of INR 109 support its defensive stance. Investor focus shifts to AI-driven offerings like TwinX and ignio, which analysts see as key catalysts for revenue and margin expansion through enterprise pilot projects scaling into contracts. Technical indicators signal oversold conditions with potential for mean reversion. Meyka AI assigns a B+ rating and projects a 12-month target of INR 3656, implying over 55% upside. Risks include slower IT spending and wage-driven margin pressure, underscoring cautious positioning for AI strategy investors.
Go toTop